Navigation Links
Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potency Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%
Date:3/19/2009

Launched at the 67th Annual American Academy of Dermatology Meeting

CRANFORD, N.J., March 19 /PRNewswire/ -- Triax Pharmaceuticals, the marketers of Locoid Lipocream(R) (hydrocortisone butyrate 0.1%) the leading mid-potency corticosteroid brand, introduces a new 4 oz. size of its recently launched Locoid(R) Lotion.

Launched at the American Academy of Dermatology (AAD) meeting in San Francisco, Locoid(R) Lotion (hydrocortisone butyrate 0.1%) contains a moisturizing vehicle to cover larger areas and hairy areas of affected skin with an elegant, non-greasy application; and is indicated to treat mild-to-moderate atopic dermatitis in patients as young as 3 months of age(1).

Locoid Lotion (hydrocortisone butyrate 0.1% lotion) is the only class 5 corticosteroid indicated for patients with AD ages 3 months of age and older. It has been proven to provide significant relief of all AD symptoms in pediatric and adult patients(1,2). By the conclusion of one study, 89% of patients had symptoms of skin-barrier disruption eliminated or reduced to mild. By Day 8, average pruritis-symptom scores were reduced to less than mild.

Dr. Adelaide Hebert, a dermatologist based in Houston, Texas remarks, "Locoid Lotion has unique properties, and is an ideal product for certain hard to treat areas such as the chest, the arms, and the legs."

Locoid Lotion is available nationwide in a 2 fl. oz. or a 4 fl. oz. bottle.

Reversible HPA axis suppression may occur with the potential for corticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Discontinue use if irritation develops.

About Triax Pharmaceuticals, LLC

Triax Pharmaceuticals is a specialty pharmaceutical company with integrated sales, marketing, and development expertise that markets a portfolio of branded dermatological products. Triax focuses on marketing dermatology products in the United States.

(1) Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008;7:266-271.

(2) Data on file.

www.locoidlotion.com

www.locoid.com


'/>"/>
SOURCE Triax Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
2. Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potentcy Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
6. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
7. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
8. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
9. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
10. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
11. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... NEW YORK (PRWEB) , ... May 05, 2016 , ... ... and swimming safety – today announced a new partnership to reach nearly 1 million ... can happen in an instant and is the leading cause of accidental death in ...
(Date:5/5/2016)... WA (PRWEB) , ... May 05, 2016 , ... ... user experience, adapted to people’s every day living patterns, Amerec, a Seattle-based steam ... computer and smart phone app. , The user interface of the app, developed ...
(Date:5/5/2016)... (NEW YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... partnership with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses ... for job seeking nurses and healthcare employers. With their enrollment into the Talent Tech ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, yet dangerous, ... the immune system and increase inflammation, both of which raise the risk of heart ... heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... finalists and winners Tuesday evening, May 3, at the 2016 ISE® Central Executive ... Scott Pettigrew, Vice President and Chief Security Officer of HMS, was selected as ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016 According to market research ... Demand Forecast to 2022 - Industry Insights by Slice Type ... and Others)" by P&S Market Research, the global computed ... and it is expected to grow at a CAGR of ... type segment is expected to witness the faster growth, CAGR ...
(Date:5/4/2016)... Research and Markets has ... Myeloma Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Multiple ... Myeloma market valuations and forecast, Multiple Myeloma ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
Breaking Medicine Technology: